Institutes to Develop Bioterrorism Vaccines

NOVEMBER 01, 2003

    The University of Maryland School of Medicine will lead a multischool effort with 16 research institutions to develop vaccines to protect against bioterroism. The Middle Atlantic region will receive a 5-year, $42-million grant from the National Institute of Allergy and Infectious Diseases. Aside from creating vaccines to protect against anthrax, smallpox, and West Nile virus, they will study antibodies that could produce short-term protection. The regional researchers will study viruses that cause hemorrhagic fevers (eg, Ebola and Marburg viruses), as well as targeting Escherichia coli and Shigella. Also, they will design better diagnostic tests and needle-free vaccinations for fast response to a biological attack or infectious disease outbreak.

    ?The events of 9-11 [in 2001] and the anthrax threats that followed made it clear that there are nefarious people out there,? said Myron M. Levine, MD, who is the regional leader. ?We have also come to realize that we are extremely vulnerable and to a great extent unprepared for biological attacks. It is crucial for us to develop preventive vaccines to protect ourselves.?



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.